BioTime CEO Dr. Michael West to Present at GTCbio 6th Annual Stem Cell Research & Therapeutics Conference

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (AMEX:BTIM) Chief Executive Officer Michael West, Ph.D. will give a presentation next week at the GTCbio 6th Annual Stem Cell Research & Therapeutics Conference, which will be held May 27-28, 2010 in Boston, Massachusetts. Dr. West will speak on “Fate Space Screening of Clonal Human ES-Derived Embryonic Progenitor Cell Lines for Chondrogenesis” in the meeting's first session, whose topic is “Differentiation of Stem Cells.”

This annual conference provides leading-edge information on developments in all areas of stem cell research, including the biology, medicine, applications, regulations, and business of stem cells. This year's sessions will include discussions of the new federal funding opportunities that are arising as alternative sources of human embryonic stem cells emerge.

Dr. West’s presentation will address BioTime’s recent research that has been directed towards the goal of generating highly purified, diverse, and scalable embryonic progenitor (EP) cell types for potential use in human cell therapy. The complete abstract of his presentation is available on the conference website at www.gtcbio.com. Dr. West’s presentation will be available on www.biotimeinc.com.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. BioTime develops and markets research products in the field of stem cells and regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. BioTime’s subsidiary OncoCyte Corporation focuses on the therapeutic applications of stem cell technology in cancer. BioTime also plans to develop therapeutic products in China for the treatment of ophthalmologic, skin, musculo-skeletal system and hematologic diseases, including the targeting of genetically modified stem cells to tumors as a novel means of treating currently incurable forms of cancer through its subsidiary BioTime Asia, Limited. Our Singapore subsidiary, ES Cell International Pte Ltd, has been at the forefront of advances in human embryonic stem (“hES”) cell technology, being one of the earliest distributors of hES cell lines to the research community. ESI has produced clinical-grade human embryonic stem cell lines that were derived following principles of good manufacturing practice and currently offers them for potential use in therapeutic product development. In addition to its stem cell products, BioTime develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime, Embryome Sciences, OncoCyte, BioTime Asia, and ESI can be found on the web at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0



CONTACT:

BioTime, Inc.
Judith Segall, 510-521-3390, ext 301
[email protected]

KEYWORDS:   United States  North America  California  Massachusetts

INDUSTRY KEYWORDS:   Stem Cells  Health  Alternative Medicine  Biotechnology  Clinical Trials  Genetics  Hospitals  Oncology  Optical  Pharmaceutical  Other Health  Research  Other Science  Medical Supplies  Science

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.